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Research Article
Phenotypic proteomic proﬁling identiﬁes a landscape of
targets for circadian clock–modulating compounds
Sandipan Ray1,2 , Radoslaw Lach3, Kate J Heesom4, Utham K Valekunja1,2, Vesela Encheva3 , Ambrosius P Snijders3,
Akhilesh B Reddy1,2
Determining the exact targets and mechanisms of action of drug
molecules that modulate circadian rhythms is critical to develop
novel compounds to treat clock-related disorders. Here, we have
used phenotypic proteomic proﬁling (PPP) to systematically de-
termine molecular targets of four circadian period–lengthening
compounds in human cells. We demonstrate that the compounds
cause similar changes in phosphorylation and activity of several
proteins and kinases involved in vital pathways, including MAPK,
NGF, B-cell receptor, AMP-activated protein kinases (AMPKs), and
mTOR signaling. Kinome proﬁling further indicated inhibition
of CKId, ERK1/2, CDK2/7, TNIK, and MST4 kinases as a common
mechanism of action for these clock-modulating compounds.
Pharmacological or genetic inhibition of several convergent ki-
nases lengthened circadian period, establishing them as novel
circadian targets. Finally, thermal stability proﬁling revealedbinding
of the compounds to clock regulatory kinases, signaling molecules,
and ubiquitination proteins. Thus, phenotypic proteomic proﬁling
deﬁnes novel clock effectors that could directly inform precise
therapeutic targeting of the circadian system in humans.
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Introduction
Circadian clocks have a profound impact on human health as they
play a central role in coordinating daily physiological and behavioral
processes. Circadian clocks, sleep–wake cycles, and metabolic net-
works systematically interact with each other to maintain a cycling
pattern in cellular functions, activity and energy utilization in ac-
cordance to a daily (near 24-h) rhythm (Bass & Takahashi, 2010;
Asher & Schibler, 2011; Ray & Reddy, 2016). In mammalian circadian
organization, the brain’s suprachiasmatic nucleus (SCN) acts as the
master clock and orchestrates synchronization of oscillators in pe-
ripheral tissues (Yamazaki et al, 2000; Reppert & Weaver, 2002). Cir-
cadian misalignment or desynchrony due to old age, neurological
disease, shift work, travel across time zones, and irregular food intake
is a rising cause of morbidity. Circadian dysfunction is associated with
an increased risk of cancers (Hoffman et al, 2008; Papagiannakopoulos
et al, 2016), diabetes (Marcheva et al, 2010; Pan et al, 2011), cardio-
vascular, and metabolic disorders (Scheer et al, 2009; Buxton et al,
2012). Consequently, small molecule compounds capable of modu-
lating circadian rhythms are promising for therapeutically targeting
diverse types of human disease linked to circadian dysregulation
(Chen et al, 2018).
High-throughput screenings of small molecules have identiﬁed a
few chemical compounds that can modulate circadian rhythm
period length in a dose-dependent manner (Hirota et al, 2008, 2010;
Chen et al, 2012; Tamai et al, 2018; Lee et al, 2019; Oshima et al, 2019).
Protein kinases, including casein kinase 1 (CK1 d/e), casein kinase 2
(CK2), JNK, glycogen synthase kinase 3-β (GSK3-β), and CDKs, are
considered as the possible targets for altering circadian clock
period (Hirota et al, 2008, 2010; Isojima et al, 2009; Walton et al, 2009;
Yagita et al, 2009; Oshima et al, 2019). However, these mechanisms
havenot been illustrated in a comprehensive and comparativemanner,
as well as the cellular effects of these compounds. In particular,
whether period-altering compounds share as yet undescribed common
downstreampathways remains an openquestion. Deﬁning such targets
would enable precise targeting in circadian drug discovery campaigns,
which is currently lacking because of a gap in our knowledge con-
cerning the mechanisms of action of circadian-active compounds.
In recent years, mass spectrometry (MS)–based quantitative pro-
teomics, more particularly thermal proteome proﬁling (TPP), has
emerged as a powerful approach in decoding molecular mechanisms
and cellular targets for novel or existing drugs in a more inclusive and
unbiased fashion (Franken et al, 2015). Themajor advantage of the TPP
methodology is the capability to measure target occupancy of drugs
by screening thousands of proteins in parallel in living cells or tissues
(Martinez Molina et al, 2013; Savitski et al, 2014). Here, we applied an
approach that we term phenotypic proteomic proﬁling (PPP), in-
tegrating multipronged proteomics approaches, including global
proteome, phosphoproteome, kinome mapping, and proteome-wide
proﬁling of thermal stability (TPP) to decipher the molecular targets
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of four circadian period–lengthening compounds (longdaysin, pur-
valanol A, roscovitine, and SP600125) in human osteosarcoma U2OS
cells—a robust and well-characterized circadianmodel system (Fig 1).
We report a comprehensive landscape of effector proteins for the
compounds that impact diverse aspects of cellular physiology. Im-
portantly, we determined several common molecular targets and
physiological effects of the circadian rhythm–modulating compounds.
Identiﬁcation of such targets will form the basis for the future de-
velopment of new drugs that can target the clockwork in a precise
manner.
Results
Circadian period–lengthening compounds reshape the proteome
and phosphoproteome
Small molecule screens using circadian bioluminescence reporter
cell lines have identiﬁed a handful of circadian period–lengthening
compounds (Hirota et al, 2008, 2010). We focused here on four
compounds—longdaysin, purvalanol A, roscovitine, and SP600125—for
in-depth mechanistic analysis because they all result in the same
circadian clock phenotype (period lengthening). As such, we hy-
pothesized that these compounds might alter cellular physiology in a
similar way and share common downstream pathways. We ﬁrst val-
idated that the compounds alter circadian period length by assaying
bioluminescence rhythms of Per2-dLuc U2OS cells. Longdaysin
drastically lengthened circadian period (35.1 ± 1.29 h, 8 μM), whereas
roscovitine (28.9 ± 0.08 h, 8 μM), SP600125 (28.6 ± 0.1 h, 7 μM), and
purvalanol A (25.2 ± 0.04 h, 8 μM) caused signiﬁcant, but less pro-
nounced, dose-dependent increases in the period length (Fig S1).
We next deﬁned the effects of the circadian rhythm–modulating
compounds on the cellular proteome by using a multiplexed tandem
mass tag (TMT)–based quantitative approach (Fig 2A). Such multi-
plexing using stable isotope labelling results in increased throughput,
higher precision, better reproducibility, reduced technical variation,
and fewer missing values than other methods (Mertins et al, 2018;
O’Connell et al, 2018). Indeed, we found that reproducibility between
the biological replicates of control (DMSO only) and compound-
treated samples was excellent (Pearson R > 0.95) (Fig S2A). There was a
slight difference in circadian phases in the treated samples (partic-
ularly for longdaysin) compared with the vehicle-treated control cells
because of the period-lengthening effects of these compounds (Fig
S1). Consequently, to specify the proteins that are altered directly by
these compounds, not because of the difference in circadian phases,
we excluded the rhythmic candidates in U2OS cells as reported earlier
by us (Rey et al, 2016) and others (Hughes et al, 2009). However, we
identiﬁed only three (Pacsin3, Tgm2, and Shc1) such overlapping
candidates. Comparative proteomic analysis of treated (10 μM) versus
control cells indicated the increased abundance of kinase inhibitors
and histone proteins and reduced levels of CDKs and other kinases
after treatment with the compounds (Table S1). On a global scale, we
observed alterations in several classes of proteins with some over-
lapping candidates (Fig S2B and C). Interestingly, histone proteins
Figure 1. PPP for the identiﬁcation of common targets for circadian period–altering compounds.
Schematic showing PPP analysis of circadian period–altering compounds. A multidimensional quantitative proteomics analysis pipeline integrating global proteome,
phosphoproteome, kinome mapping, and proteome-wide proﬁling of thermal stability.
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Figure 2. Circadian period–lengthening compounds induced alterations in U2OS proteome and phosphoproteome.
(A) Schematic representation showing the labelling strategy used in TMT 10-plex quantitative proteomics and phosphoproteomics experiments. (B) Pie charts showing
functional classiﬁcation (protein class) for the differentially abundant proteins (pAdj < 0.05) identiﬁed in longdaysin-, purvalanol A–, roscovitine-, and SP600125-treated cells. (C)
Proteomaps (KEGG Pathways gene classiﬁcation) of the differentially abundant proteins identiﬁed in cells treatedwith circadian period–lengthening compounds. (D) Volcano plots
showing P-values (−log10) versus ratio of group mean of phosphosites abundance (log2) in control (DMSO) and longdaysin-treated cells. Red, up-regulated; green, down-
regulated (adjusted P-value < 0.05), and blue, not signiﬁcantly altered phosphosites. Selected differentially abundant phosphosites are labelled. Phosphosites labelled in pink
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(H3 and H4) were consistently altered across all the compound-treated
conditions (Fig S2C). Importantly, rhythmic acetylation/deacetylation
of histones (H3 and H4) at multiple clock target genes plays crucial
roles in the mammalian circadian clock (Etchegaray et al, 2003).
Differentially abundant proteins upon treatment with circadian
rhythm–modulating compounds were largely nucleic acid–binding
proteins, kinases, signaling molecules, ribosomal proteins, enzyme
modulators, and transcription factors (Fig 2B and C). These proteins
are associated with diverse, vital, physiological pathways, including
translation, signal transduction cascades, DNA damage and meth-
ylation, and metabolism (Fig S2D).
Reversible protein phosphorylation plays a central role in circadian
rhythmicity (Virshup et al, 2007) and rhythmic tuning of signaling
pathways (Robles et al, 2017). Therefore, we asked whether the cir-
cadian rhythm–modulating compounds change the phosphorylation
pattern of the cellular proteome by using multiplexed quantitative
phosphoproteomics. Comparison of the cellular phosphoproteomes
demonstrated alteredmean abundance (against control-vehicle only)
of multiple phosphosites in compound-treated cells (Fig S3A). Many of
these altered phosphosites were modulated in common by multiple
compounds (Figs 2D and S3B). Of note, 123 phosphosites were sig-
niﬁcantly altered (pAdj < 0.05) by at least one of the compounds. This
allowed effective separation of control versus compound-treated cells
by hierarchical clustering (Figs 2E and S3C). Treatment with the
compounds reduced phosphorylation of many proteins involved in
intracellular signal transduction, apoptosis, the cell cycle and protein
translation (Figs 2F and S3D). Importantly, some altered phospho-
proteins such as MCM2, BCLAF1, and HSPB1 are substrates of clock-
regulating kinases, including CKs, CDKs, and MAPKs (Montagnoli et al,
2006; Franchin et al, 2018). Collectively, the proteomics and phos-
phoproteomics assessments indicatemodulation of a diverse range of
cellular targets by these period-lengthening compounds.
Circadian period–lengthening compounds inhibit several kinases
It is widely recognized that protein kinases serve as key regulators
of mammalian circadian clocks (Reischl & Kramer, 2011). CK1 d/e,
CK2, AMP-activated protein kinases (AMPKs) and many other protein
kinases regulate phosphorylation, functional activity, complex for-
mation and degradation of the core transcriptional clock proteins
including PER, CRY, CLOCK, BMAL1 and REV-ERB (Eide et al, 2002; Lamia
et al, 2009; Lipton et al, 2015; Tamaru et al, 2009; Narasimamurthy et al,
2018). CK1 also has regulatory effects in temperature compensation of
non-transcriptional oscillators in human red blood cells (Beale et al,
2019). Consequently, small-molecule kinase inhibitors are consid-
ered as themost promising candidates for tuning circadian period in
mammalian clocks for therapeutic beneﬁt (Yagita et al, 2009). To this
end, the four circadian period–altering compounds we studied here
are also known kinase inhibitors–longdaysin (CK1alpha/delta and
ERK2 inhibitor) (Hirota et al, 2010), purvalanol A (CDK inhibitor) (Bain
et al, 2007), roscovitine (CDK and ERK inhibitor) (Bain et al, 2007;
Whittaker et al, 2018), and SP600125 (JNK and CDK inhibitor) (Bennett
et al, 2001). However, comprehensive proﬁling of the whole kinome
with these compounds has not been investigated earlier, which is
crucial for the identiﬁcation of their common and novel targets.
Desthiobiotin nucleotides can selectively enrich and proﬁle target
enzyme classes to evaluate the speciﬁcity and afﬁnity of diverse
enzyme inhibitors (Patricelli et al, 2007; Cravatt et al, 2008) (Fig S4A).
MS can thenbeused for kinomeanalysis using suchnucleotide probes,
allowing global delineation of the regulated kinases in treated cells
(McAllister et al, 2013). We used desthiobiotin-ATP enrichment in
combination with multiplexed quantitative proteomics to measure
kinase abundances in human U2OS cells treated with circadian
period–lengthening compounds (Fig 3A). We obtained more than
85% enrichment of the desthiobiotin-ATP peptides (Fig S4B), which
allowed quantiﬁcation of many extremely low abundance kinases
that are generally not detected in regular quantitative proteomics
workﬂows. We measured abundance and inhibition proﬁles for 174
kinases and observed reduced activity (major, moderate, or minor
effects) of several kinases induced by the compounds (Fig S4C). Of
note, a number of kinases, including CK1d, ERK1/2, CDK7, CDK2, CAMK1d/
2d, MST4/STK26, and TNIK were detected as overlapping targets for
the compounds (Fig 3B). To this end, CK1a/d/e and ERK2 were
identiﬁed earlier as the targets responsible for period-lengthening
in mammalian cells (Isojima et al, 2009; Hirota et al, 2010).
We next validated the MS ﬁndings by using radiometric “HotSpot”
assays. This assay directly measures kinase catalytic activity towards a
speciﬁc substrate (Fig S5A) and is a well-established method for ki-
nase inhibition analysis (Anastassiadis et al, 2011; Duong-Ly et al, 2016).
Radiometric assays similarly demonstrated inhibition of multiple
kinases by the circadian rhythm–modulating compounds, with a
few overlapping targets (Fig S5B). Importantly, we saw functional
inhibition (>50%) of CK1d, CDK7, CDK2, and MST4 by all of these
compounds (Fig 3C), with SP600125 inhibiting the maximum
number of kinases (Fig S5B). We further measured half-maximum
inhibitory concentration (IC50) for the compounds towards ﬁve
overlapping target kinases (CK1d, CDK2, CAMK2d, MST4, and TNIK) using
a 10-dose inhibition series (Fig 3D). The most affected kinases were
CK1d and CDK2 with an IC50 < 5 μM for all four compounds, whereas
purvalanol A and SP600125 inhibited TNIK speciﬁcally with a more
potent IC50 (<0.5 μM) (Fig S6).
Taken together, the results from desthiobiotin-ATP enrichment
and radiometric assays suggest that the circadian rhythm–
modulating compounds exhibit their effects by inhibiting multiple
protein kinases. Therefore, we examined the distribution of the
identiﬁed kinase targets in their families. We found that the
compounds inhibited kinases from all major typical kinase sub-
families, with the highest number of targets (10) from CMGC (CDKs
and MAPKs) and calmodulin/calcium-regulated kinase (CAMK)
subfamilies (Fig 3E). Multiple members of automatic gain control
(AGC) and STE subfamilies were also targets of the compounds.
Importantly, several members of the CMGC (ERK2/MAPK1, CDK7, and
CDK2), CAMK (CAMK1d and 2d), STE (MST4 and TNIK), and CK (CK1d)
subfamilies were overlapping targets for the compounds (Fig 3F).
were also altered by other circadian period–altering compounds. (E) Hierarchical cluster analysis of 123 phosphosites that are altered by circadian period–lengthening
compounds. (F)Relative abundance (against DMSO control) of the commonly altered phosphoproteins in longdaysin-, purvalanol A–, roscovitine-, and SP600125-treated cells. Data
are represented asmean ± SEM (n = 3). One-way ANOVA, Dunnett’s test. *** indicates P < 0.0001, ** indicates 0.0001 < P < 0.001, * indicates 0.001 < P < 0.01, and NS indicates P > 0.05.
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Figure 3. Circadian period–altering compounds inhibit several kinases in the mammalian system.
(A) Schematic representation showing kinase proﬁling of U2OS cell line in the presence of circadian period–lengthening compounds (longdaysin, purvalanol A,
roscovitine, and SP600125) by using desthiobiotin nucleotide probes in combination with TMT-based quantitative proteomics (biological replicates, n = 3). This workﬂow
allows targeted capture and quantiﬁcation of kinases using the active-site probes (desthiobiotin-ATP). (B) Venn diagram representing the overlap between the kinases
inhibited (pAdj < 0.05) by different circadian period–lengthening compounds. (C) Activity proﬁles of different kinases in the presence of circadian period–lengthening
compounds (100 μM, n = 3) measured by a radiometric “HotSpot” assay. (D) 10-dose inhibition curves (threefold serial dilution starting at 100 μM) representing
overlapping target kinases for different circadian period–lengthening compounds. (E) Distribution of the identiﬁed kinase targets of the circadian period–altering
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Thus, kinome analysis deﬁnes overlapping targets for the circadian
rhythm–modulating compounds, many of which were not pre-
viously known to be associated with clock function.
To establish a mechanistic connection between the identiﬁed ki-
nase targets for the period-lengthening compounds and the clock-
work, we next tested whether inhibitors of overlapping kinase targets
of the compounds prolong cellular circadian rhythms. This would be
expected if they were truly affecting the molecular clock in a speciﬁc
manner. We used LH846 and D4476 (CK1d inhibitors), SU9516 (CDK2
inhibitor), BS-181 HCl (CDK7 inhibitor), Hesperadin (MST4 inhibitor),
and KY-05009 (TNIK inhibitor) to inhibit each respective kinase. We
proﬁled circadian rhythms of cells treated with each inhibitor by
monitoring bioluminescence rhythms of Per2-dLuc U2OS reporter
cells. Most of the inhibitors, particularly LH846, D4476, and SU9516,
led to a substantial dose-dependent increase in the period length
(Fig 4). Whereas LH846, D4476, and BS-181 have previously been
Figure 4. Dose-dependent effects of kinase inhibitors in mammalian circadian period length.
(A, B, C, D, E) Dose-dependent effect for inhibitors of (A) casein kinase I (CK1d)—LH846 and D4476, (B) CDK2—SU9516, (C) CDK7—BS-181 HCl, (D) serine/threonine-protein
kinase 26 (MST4)—Hesperadin, and (E) TRAF2 and NCK-interacting protein kinase (TNIK)—KY-05009 were evaluated. Luminescence rhythms of Per2-dLuc U2OS cells were
monitored in the presence of 11 different concentrations of these six kinase inhibitors (threefold serial dilution starting at 100 μM). Period parameter was obtained by the
curve ﬁtting and plotted against the ﬁnal concentration of the compounds (adjusted by keeping the control Per2-dLuc cells period length as 24 h). Dose–response
curves showing the circadian period length alterations with the top seven concentrations of the compounds (100–0.14 μM). Data are the representative of multiple
biological replicates (n = 4, mean ± SEM). One-way ANOVA, Dunnett’s test. *** indicates P < 0.0001, ** indicates 0.0001 < P < 0.001, and * indicates 0. 001 < P < 0.05.
compounds in the kinase family. Kinase proﬁling was performed combining the targets obtained in quantitative proteomics and in radiometric assay. (F) Kinome tree
illustrating the kinase targets of circadian period–altering compounds. Kinome tree structured courtesy of Cell Signalling Technology, Inc. (www.cellsignal.com) and
annotated using KinMap online tool.
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reported to induce period lengthening (Hirota et al, 2010; Lee et al,
2011; Ou et al, 2019), the other inhibitors were not known to have
circadian period–modulating ability. Notably, we also observed
dose-dependent phase-shifting effects of KY-05009, SU9516, BS-181
HCl, and D4476 (Fig S7). Such phase-shifting agents might be
beneﬁcial to treat jetlag, or aid recovery from shift work–associated
health problems (Wallach & Kramer, 2015). Thus, inhibiting the
kinases that we identiﬁed as the overlapping targets for the period-
lengthening compounds phenocopied the effects of the com-
pounds themselves, demonstrating their functional importance as
clock modulators.
Circadian rhythm–modulating compounds interact with clock
machinery through diverse signaling pathways
We next evaluated the effects of RNAi-mediated inhibition of the
kinases that were identiﬁed as overlapping targets for multiple
circadianperiod–modulating compounds inour integratedproteomics-
phosphoproteomics and kinome proﬁling analyses. We used data
from the BioGPS circadian genomic siRNA database (Zhang et al,
2009) and determined that siRNA knockdown of these kinase
targets prolongs period length in circadian oscillations (Fig S8A). Of
note, knockdown of most of the kinase targets (seven of nine) with
two independent siRNA pairs lengthens the circadian period: CDK2
(26.9/39.3 h), CDK7 (26/27.5 h), CK1d (26.6/27.2 h), CK2a (31.5/31 h),
ERK1/MAPK3 (27.1/48 h), ERK2/MAPK1 (26.3/27.5 h), and MST4 (26.03/
27.6 h) (Fig S8B).
Alterations in the activity of several kinases by the circadian
modulators suggested an interaction between the molecular cir-
cadian oscillator and different signaling pathways to maintain a
robust period length. We, therefore, determined the nature of these
connections using pathway and network analyses. Ingenuity
pathway analysis (IPA) indicated cell signaling as the top-scoring
overlapping network for longdaysin (score: 41, focus molecule: 19/
35), roscovitine (score: 39, focus molecule: 18/35), and SP600125
(score: 59, focus molecule: 28/35) (Fig S9). We next analysed the
possible interactions among the inhibited kinases (and altered
phosphoproteins) and clock components using the STRING data-
base. We found a dense interaction network (protein–protein in-
teraction [PPI] enrichment P-value = 3.04 × 10−7) among the clock
components and the targets for circadian modulator compounds
(Fig 5A). Signiﬁcantly, we identiﬁed the common kinase targets
(CK1d, MAPKs, and CDKs) for the circadian rhythm–modulating
compounds as the major connecting hubs in the network. More-
over, siRNA knockdown of many target kinases and phosphopro-
teins lengthened the molecular clock period (Fig 5A).
A plethora of signaling pathways were overrepresented for the
long-period targets, including B-cell receptor signaling (false dis-
covery rate [FDR] = 9.09 × 10−20), MAPK signaling (FDR = 1.13 × 10−18),
hepatocyte growth factor signaling (FDR = 1.46 × 10−16), NGF signaling
(FDR = 2.11 × 10−16), AMPK signaling (FDR = 3.90 × 10−14), mTOR sig-
naling (FDR = 7.88 × 10−13), EGF signaling (FDR = 5.22 × 10−10), and
SAPK/JNK signaling (FDR = 2.89 × 10−08) (Fig 5B). Furthermore, we
determined that components of these signaling pathways cross-
talk with each other and play vital roles in other pathways (Fig 5C).
In line with this, earlier studies have demonstrated that core clock
components link circadian timing and mTOR (Cornu et al, 2014;
Lipton et al, 2015), insulin (Zhang et al, 2009), MAPK (Coogan &
Piggins, 2004), and AMPK (Lamia et al, 2009) signaling pathways.
Taken together, our ﬁndings indicate that connections between
signaling pathways form a multidimensional network that acts in
concert with clock components to maintain circadian oscillations in
daily physiological and metabolic processes.
TPP deﬁnes additional cellular targets for circadian modulators
Recent studies have demonstrated that changes in the thermal
stability of proteins upon ligand binding can be used to identify
targets of small molecules or drugs (Martinez Molina et al, 2013;
Savitski et al, 2014; Miettinen et al, 2018). TPP determines melting
curves for thousands of proteins and enables potential drug
targets to be found by evaluating the differential stability
(change in melting temperature, ΔTm) of proteins under ligand-
bound and control (unbound) conditions (Franken et al, 2015).
We, therefore, applied TPP to decipher potential molecular
targets of longdaysin, roscovitine, and SP600125 in U2OS cells
(Fig 6A). We were able to identify 5,400 proteins in control
(vehicle only) and compound-treated cells and performed
melting curve analysis on nearly 75% of the detected proteins
that were quantiﬁed in all the control and compound-treated
samples (Fig S10A).
TPP revealed direct binding (a positive ΔTm shift) of circadian-
modulating compounds to clock regulatory kinases (CKs and
CDKs) and a number of kinase regulators and signaling medi-
ators including CD40, CD59, F-box proteins, and RNF181 (Figs 6B–D
and S10–S12). Moreover, in concordance with our ﬁndings from
differential quantitative proteomics, where we identiﬁed al-
tered expression of many ribosomal proteins involved in protein
translation (Figs 2C and S1D), we found Tm shifts for the ribosomal
proteins RPL36 and RPL37 (Figs S10 and S12). Interestingly, a re-
cent study showed that the core circadian clock rhythmically
interacts with the translational machinery via BMAL1 (Lipton et al,
2015). We did not observe (or were unable to measure) a sig-
niﬁcant Tm shift for some of the kinase targets (MST4, TINK, and
ERKs) that we found using desthiobiotin-ATP enrichment and
radiometric assays (see above). We consider that there are three
possible reasons for this (1) the proteins were affected (e.g.,
downstream targets); but were not direct binding partners of the
circadian rhythm–modulating compounds; or (2) they were not
stabilized by compound binding; or (3) they were not quantiﬁed in
each MS run (without an enrichment method) because of their low
abundance.
We next compared the overlapping binding targets for the
compounds and identiﬁed 10 candidates that were commonly
regulated (Figs 6E and F, and S13A). The magnitude of the Tm shifts
induced by longdaysin, roscovitine, and SP600125 was fairly cor-
related (R2 > 0.75), indicating that the compounds bind overlapping
targets with comparable afﬁnities (Fig S13B). Many of the over-
lapping targets, including FBX21, RPL37, RABEP1, and CSTF2T, are
associated with the protein polyubiquitination machinery and
protein translation (Figs 6F and S13C). Like phosphorylation,
ubiquitination, which is largely mediated by F-box proteins, also
modiﬁes clock proteins to regulate circadian timekeeping in
mammals (Hirano et al, 2013; Xing et al, 2013). In particular, F-box
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Figure 5. Circadian period–altering compounds target multiple signaling pathways.
(A) Interaction network (PPI enrichment P-value 3.04 × 10−7) among phosphoproteins (green) and kinases (blue) modulated by circadian period–altering compounds.
siRNA knockdown of the candidates highlighted with a golden yellow dot induces long period length in circadian oscillations (>26 h at least in one of the two independent
siRNA pairs). siRNA knockdown data obtained from BioGPS circadian layout database (http://biogps.gnf.org/circadian/) (Zhang et al, 2009). Core clock (red) and additional
clock (pink) components are also integrated into the network. Association network is generated using the STRING database involving only high conﬁdence (score > 0.8)
interactions. (B) Signaling pathways associated with the phosphoproteins and kinases altered by circadian period–modulating compounds (analysed using IPA, top 15,
FDR < 0.05). (C) Interaction network among the signaling pathways associated with the phosphoproteins and kinases altered by circadian period–modulating compounds.
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Figure 6. Proteome-wide proﬁling of thermal stability after treatment with circadian rhythm–modulating compounds.
(A) Schematic representation of differential proﬁling of the effects of three circadian period–altering compounds on the TPP in U2OS cells using TMT-based quantitative
proteomics. The obtained TMT reporter ion intensities were used to ﬁt melting curves and calculate the melting temperature Tm of each protein separately in control
(vehicle only) and compound-treated conditions. (B, C, D) Melting curves for selected kinases, signaling molecules, and apoptosis regulators showing Tm shift (positive)
after treatment with longdaysin (B), roscovitine (C), and SP600125 (D). Data from two independent replicate experiments are shown (please see Figs S10–S12 for further
details). (E, F) Melting curves for target proteins stabilized by multiple circadian period–altering compounds. Mean values from two independent replicates are
represented.
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proteins embedded in mammalian circadian feedback loops are
vital for period determination and robustness of the clock (Godinho
et al, 2007; Shi et al, 2013). Importantly, genetic siRNA knockdown of
the target proteins results in long period circadian rhythms,
phenocopying the effects of the circadian rhythm–modulating
compounds: RABEP1 (26.03 ± 0.92 h), FBX21 (25.96 ± 0.34 h), and
CSTF2T (32.85 ± 4.48 h) (Fig S13D). As a further genetic test of the
speciﬁcity of the circadian rhythm–modulating compounds to-
wards their various targets, we determined their effects on the
circadian clock of the prokaryotic cyanobacterium Synechococcus
elongatus. This organism is the simplest circadian model system
and does not possess the target binding proteins that we identiﬁed
in our integrated proteomics analysis in mammals. Strikingly, we
did not ﬁnd any effect of the compounds in cyanobacteria, in-
dicating their speciﬁcity towards the eukaryotic clockwork and to
the targets that we identiﬁed in human cells (Fig S14). Thus, un-
biased proteome-wide proﬁling of thermal stability delineates a
complementary set of molecular targets for circadian rhythm
modulators, alongside novel kinase networks, which were not known
previously.
Finally, to obtain a comprehensive depiction of the mechanisms
of action and cellular effects of the circadian rhythm–modulating
compounds, we investigated the possible interactions among the
altered proteins, phosphoproteins, inhibited kinases, and binding
targets identiﬁed by our multidimensional proteomics analyses.
Considering only high conﬁdence interactions (score > 0.8), we
identiﬁed several overlapping networks (PPI enrichment P-value
9.06 × 10−11) involving phosphorylation, cell cycle, signaling, protein
localization, and regulation of translation, metabolism, and apo-
ptosis (FDR < 0.01) (Fig S15). In addition to circadian timekeeping, the
effects of the circadian rhythm–modulating compounds on the cell
cycle, cell signaling, and apoptosis ﬁts with the growing links be-
tween clock dysregulation and tumorigenesis (Lee et al, 2011;
Oshima et al, 2019). Altogether, our results demonstrate that the
effects of circadian rhythm–modulating compounds are not re-
stricted to a handful of known targets, but rather that they function
Figure 7. Schematic depicting the mechanisms of
action for circadian rhythm–altering compounds in
mammalian systems.
The major molecular targets and cellular responses
induced by these compounds are shown. Circadian
period–altering compounds regulate clock machinery
through multiple signaling pathways, including MAPK,
AMPK, and mTOR, and ubiquitination mediated by
F-box proteins. Modulation of circadian timekeeping by
these compounds causes alterations in several proteins
involved in cell proliferation, apoptosis, and tumor
suppression (the schematic diagram is structured
using the information obtained from IPA).
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by acting on multiple cellular targets embedded within diverse, but
well-deﬁned, physiological pathways (Fig 7).
Discussion
In recent years, systems level approaches have contributed im-
mensely to elucidate complex mechanisms of the circadian clocks
(Millius & Ueda, 2017; Rey et al, 2018). Here, we applied PPP to
decipher the protein targets of entities that result in the same
phenotype. In this case, we used this approach to identify mech-
anistic targets of circadian–modulating compounds that all
lengthen the clock period. We identiﬁed many new convergent
targets for circadian rhythm–modulating compounds besides their
canonical effectors, including various kinases. Most kinase in-
hibitors that target the ATP-binding site inhibit multiple kinases
and even different groups of kinases because of the evolutionarily
conserved nature of the binding site (Anastassiadis et al, 2011).
Several potential small molecule drug candidates and many ap-
proved drugs also have multiple physiological targets, which often
cumulatively contribute to a complex mechanism of action (Keiser
et al, 2009; Anighoro et al, 2014). In light of this, multi-target activity
for most promising circadian period–modulating compounds is not
adequately deﬁned (He & Chen, 2016). Here, we have demonstrated
that circadian rhythm–modulating compounds with known primary
targets also act on several other molecules and downstream
pathways to regulate circadian timekeeping (Fig 7). The diversity of
targets for circadian rhythm–altering compounds revealed here by
PPP provides additional explanations for earlier observations in-
dicating that CK1 d/e-targeting compounds induce much higher
period-lengthening effects than CK1d gene knockout (Etchegaray
et al, 2009; Isojima et al, 2009) and circadian rhythm–modulating
compounds such as longdaysin cause period lengthening even in
CK1d deﬁcient cells, that is, in the absence of its primary target
(Hirota et al, 2010).
Importantly, a number of regulatory components of the clock
machinery are thought to also function beyond their role in cir-
cadian rhythmicity. As such, we observed that clock modulator
compounds regulate diverse physiological pathways alongside
biological rhythms, including protein translation, posttranslational
modiﬁcations, metabolism, cell proliferation, and apoptosis. We
found that circadian rhythm–modulating compounds directly
regulate a multi-kinase network mainly revolving around CK1, ERKs,
CDKs, TNIK, and STK26. Protein kinases regulate functions of nu-
merous eukaryotic proteins (Manning et al, 2002) and are, therefore,
fundamental to cellular and organismal function (Chang & Karin,
2001; Saxton & Sabatini, 2017). Moreover, protein kinases are cur-
rently one of the most important group of pharmacological targets
because irregular phosphorylation is a cause or consequence of a
signiﬁcant number of human diseases (Cohen, 2002; Ferguson &
Gray, 2018; Steinberg & Carling, 2019). Consequently, circadian period
or phase-altering compounds that act on multi-kinase targets
to modulate daily rhythms are promising broadspectrum drug
candidates.
The convergent targets for circadian rhythm–modulating com-
pounds identiﬁed here augment our understanding of their mode
of action, whereas their effects on different physiological pathways
will aid the elucidation of off-targets and possible side effects of
these compounds and their future derivatives. A recent study dem-
onstrated the multi-target effects of NCC007, a newly developed
compound with structural similarity to longdaysin, which is also a
potent period-lengthening compound (Lee et al, 2019). The kinase
targets for NCC007 and longdaysin are similar (CK1d, CK1α, CDK 2/7,
and MAPK1), suggesting that once all possible targets for these
compounds are adequately characterized and more efﬁcient new
compounds could be synthesized through structural modiﬁcations.
However, it is imperative to understand the cellular effects induced
by these drug-like compounds to deﬁne their possible side effects,
because drug discovery to approval and clinical translation to the
market is an extremely stringent procedure with a high rate of
failure due to off-target effects. In this regard, it will also be im-
portant to investigate circadian clock modulators from existing
approved drugs based on the targets and pathways identiﬁed in our
study. For instance, dehydroepiandrosterone (DHEA) was identiﬁed
earlier as a circadian period–shortening compound through screening
approved drug compounds (Tamai et al, 2018), and similar approaches
could identify drugs for repurposing as circadian-active agents.
In summary, we provide here a comprehensive atlas for the
mechanisms of action and cellular responses for circadian period–
lengthening compounds by using PPP. We also demonstrate dose-
dependent phase-shifting effects of a few kinase inhibitors.
Surprisingly, we found that the mechanism of circadian rhythm
modulation is not restricted to previously deﬁned primary targets,
but rather that a multi-kinase network is involved. The compounds
studied interact with the clock machinery through diverse signaling
pathways including MAPK, AMPK, andmTOR. Importantly, serine and
threonine kinases (MAPKs and CKs) are in general highly conserved
in eukaryotes. We also found ubiquitination mediated by an F-box
protein (FBX21) as a common target for these compounds. It re-
mains to be seen if these compounds induce dose-dependent
period and phase shifts in diverse types of eukaryotic organisms
by regulating similar mechanisms, which could be an interesting
continuation of the present study. Collectively, we anticipate that
our ﬁndings will provide new opportunities for developing novel
therapeutics targeting circadian rhythms. More generally, the PPP
approach established here provides a paradigm for numerous
potential other phenotype-centric molecular analyses. For exam-
ple, PPP could easily be applied to determine de facto cellular
effectors for cell cycle modulators (for cancer drugs) or CRISPR
activators and inhibitors (for modulating genome editing) in any
model system ranging from bacteria to humans to dissect their
mechanisms of action in unprecedented detail.
Materials and Methods
Cell culture
Per2-dLuc U2OS osteosarcoma and Bmal1-dLuc U2OS osteosar-
coma reporter cell lines were gifts from Dr Andrew Liu, University of
Memphis, USA (Liu et al, 2008). Wild-type U2OS (ATCC-HTB-96), Per2-
dLuc U2OS, and Bmal1-dLuc U2OS cells were grown in DMEM
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containing 4.5 g/l glucose supplemented with 10% (vol/vol) new-
born calf serum, 1% (vol/vol) GlutaMAX supplement, 1% (vol/vol)
penicillin–streptomycin, and 0.2% (vol/vol) MycoZap. The cells were
cultured at 37°C, 5% CO2 in a standard humidiﬁed incubator.
S. elongatus (strain AMC149) was a gift from Dr Carl Johnson,
Vanderbilt University, USA (Kondo et al, 1993). Cyanobacteria cells
were grown in BG-11 medium with aeration in constant light (LL) of
100 μE s−1 m−2 at 30°C as described earlier (Edgar et al, 2012). The
D730nm was maintained between 0.27 and 0.45 by dilution with fresh
medium. The cultures were given a 12-h dark pulse to synchronize
the clocks, and then returned to constant light.
Cell-based circadian luminescence assays
To perform bioluminescence recordings, Per2-dLuc U2OS and/or
Bmal1-dLuc U2OS cells were grown to conﬂuence and were
synchronised by changing the medium to “air medium” (Hastings
et al, 2005)—DMEM supplementedwith 5 g/l glucose, 20mMHepes, 1%
penicillin–streptomycin, 0.035% NaHCO3, 10% newborn calf serum,
1% GlutaMAX, 0.5% B-27 Supplement, 1 mM luciferin, 1% non-
essential amino acids, and 0.2% MycoZap Plus-PR. Circadian
period–altering compounds (dissolved in DMSO, ﬁnal 0.5% DMSO)
were then added in the air medium to reach the different desired
concentrations. Bioluminescence assays were performed following
the same protocol as described previously (Rey et al, 2016). In brief,
the assays were performed at 37°C using 384-well plates in custom-
made bioluminescence recording systems (Cairn Research Ltd)
composed of a charge-coupled device camera (Andor iKon-M 934)
mounted on the top of an Eppendorf Galaxy 170R CO2 incubator.
Images were generated from integrated photon counts over 25 min
every 30 min using Metamorph software (Molecular Devices). For
bioluminescence recordings in S. elongatus (AMC149), psbAIp:luxAB
was used as a reporter, using earlier described protocols (Edgar et
al, 2012). Exported images were composed into image stacks and
were quantiﬁed in a time series using a custom script in NIH ImageJ
software, applying the “Multi Measure” plugin. A modiﬁed version of
the R script “CellulaRhythm” (Hirota et al, 2008) was used to analyse
bioluminescence data traces, and period analysis was performed
by sine-wave ﬁtting.
MS sample preparation
Conﬂuent U2OS cell cultures grown in 150-mm dishes (2 × 107) were
treated with circadian period–altering compounds (longdaysin [cat.
no. SML0127; Sigma-Aldrich], purvalanol A [cat. no. P4484; Sigma-
Aldrich], roscovitine [cat. no. 557360; Calbiochem] and SP600125
[cat. no. S5567; Sigma-Aldrich]) to a ﬁnal concentration of 10 μM
dissolved in DMSO (100 μl of DMSO; <0.5% of the total culture
volume) or an equivalent amount of DMSO (vehicle only). After 48-h
incubation with the compounds or DMSO, the cells were harvested
by trypsinization, washed twice in PBS, and were lysed in 500 μl lysis
buffer containing 50 mM Hepes (pH 8.5), 8M urea, 1% NP-40, pro-
tease and phosphatase inhibitors, and benzonase nuclease. Then
mild sonication was applied for 15 min (30 s on, 30 s off; medium
power) using a Bioruptor Standard (Diagenode) instrument and
lysates were centrifuged at 16,000g for 20 min at 4°C. Supernatants
were carefully separated and transferred into new microcentrifuge
tubes. Protein precipitation was performed with 1:6 volume of
prechilled (−20°C) acetone overnight at 4°C. After overnight in-
cubation, the lysates were centrifuged at 14,000g for 15 min at 4°C.
Supernatants were discarded without disturbing pellets, and the
pellets were air-dried for 2–3 min to remove residual acetone. Then
the pellets were dissolved in 500 μl 100 mM triethylammonium
bicarbonate (TEAB) buffer.
Multiplexed quantitative proteomics and phosphoproteomics
Protein concentration in each sample was determined by Pierce
BCA Protein Assay Kit (cat. no. 23225; Thermo Fisher Scientiﬁc)
following the manufacturer’s instructions. 300 μg protein per
condition was transferred into new microcentrifuge tubes and 15 μl
of the 200 mM tris(2-carboxyethyl)phosphine (TCEP) was added to
reduce the cysteine residues, and the samples were incubated at
55°C for 1 h. Subsequently, the reduced proteins were alkylated with
375 mM iodoacetamide (freshly prepared in 100 mM TEAB) for 30
min under dark condition at room temperature. Then, trypsin
(Trypsin Gold, Mass Spectrometry Grade; cat. no. V5280; Promega)
was added at a 1:40 (trypsin: protein) ratio and the samples were
incubated at 37°C for 12 h for proteolytic digestion. After in-solution
digestion, control (DMSO) and circadian period–altering com-
pounds treated samples were labelled with TMT isobaric label
reagents (TMT, 10-plex) following the manufacturer’s instructions
(cat. no. 90113; Thermo Fisher Scientiﬁc) (Fig 2A). Peptide samples
were labelled with the corresponding TMT 10-plex reagent for 1 h 30
min at room temperature. The reactions were quenched using 5 μl
of 5% hydroxylamine for 30 min and 10% of the TMT-labelled peptides
were used for global proteomics analysis, whereas the remaining 90%
was subjected to phosphopeptide enrichment. Phosphopeptides
enrichment was performed using Pierce TiO2 Phosphopeptide En-
richment and Clean-up Kit (cat. no. A32993; Thermo Fisher Scientiﬁc)
as per the manufacturer’s instructions. TMT-labelled peptides were
desalted using C18 Spin Tips, dried by vacuum centrifugation, and
stored at −80°C until mass spectrometric analysis.
Kinase proﬁling using desthiobiotin nucleotide probes
U2OS cells (2 × 107) were lysed using Thermo Fisher Scientiﬁc Pierce
IP Lysis Buffer and desalted using Thermo Fisher Scientiﬁc 7K Zeba
Spin Desalting Columns following the manufacturer’s protocol
(Pierce Kinase Enrichment Kit with ATP Probe, cat. no. 88310). Cell
lysates (1 mg in 500 μl Reaction Buffer) were treated with 10 μl of 1M
MnCl2 for 1 min at room temperature. Subsequently, the cell lysates
(1 mg) were treated with 25 μM of longdaysin or purvalanol A or
roscovitine or SP600125, whereas the control samples were treated
with DMSO (vehicle) only (Fig 3A). Compound-treated and control
cell lysates were labelled with 5 μM of desthiobiotin-ATP (Thermo
Fisher Scientiﬁc) for 10 min at room temperature. Desthiobiotin-ATP
labelled proteins were reduced and alkylated before buffer exchange
intodigestionbuffer (20mMTris, pH8.0, and 2Murea). Then the samples
were tryptically digested for 4 h; active-site peptides were captured
with streptavidin agarose resin and eluted using 50% acetonitrile/
0.1% TFA. TMT labelling (10-plex) of the kinase-enriched samples
was carried out following the same protocol as described above.
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TPP using intact cells
Sample preparation (intact live U2OS cells) for TPP was carried out
following the same protocol as described by Franken et al (2015)
with slight modiﬁcations. In brief, conﬂuent U2OS cell cultures
were treated with circadian period–altering compounds (10 μM of
longdaysin, roscovitine, or SP600125) dissolved in DMSO or an
equivalent amount of DMSO (vehicle only). Incubation of cells with
the compounds and vehicle was conducted in parallel at 37°C. TPP
experiments were performed, including two biological replicates for
each condition. The cells were washed twice with ice-cold PBS and
were harvested by trypsinization after incubation with circadian
period–altering drugs. The cells were resuspended in ice-cold PBS
containing 0.4% NP-40 and protease inhibitors, and the resulting
cell suspension was divided into 10 0.2-ml PCR tubes (50 μl each).
Detergent Nonidet P-40 (NP-40) was included in buffer to detect
transmembrane protein–small molecule interactions (Reinhard
et al, 2015). Compound- and vehicle-treated cells were then heated
in parallel in a PCRmachine for 3 min to the respective temperature
(10 temperatures: 37°C, 41°C, 44°C, 47°C, 50°C, 53°C, 56°C, 59°C,
63°C, and 67°C) (Fig 6A), followed by a 3-min incubation at room
temperature. Subsequently, the cells were snap-frozen in liquid
nitrogen for 1 min and were thawed brieﬂy in a water bath at 25°C
and were transferred on ice and resuspended by using a pipette.
This freeze–thaw cycle was repeated two times. The entire content
was centrifuged at 100,000g for 20 min at 4°C. After centrifugation,
30 μl of the supernatant was transferred into a new tube. Protein
concentration in each sample was determined by Pierce BCA
Protein Assay Kit following the manufacturer’s instructions. 50 μg of
the lowest temperature sample and an equivalent volume of the
other temperature-point samples were analysed using SDS–PAGE
for a quality control check. TMT labelling (10-plex) was carried out
following the same protocol as described above. TMT-labelled
peptides were fractionated using Pierce High pH Reversed-Phase
Peptide Fractionation Kit (cat. no. 84868; Thermo Fisher Scientiﬁc)
following the manufacturer’s instructions. All fractions (eight
fractions in each set) were desalted using Pierce C18 Spin Tips, dried
by vacuum centrifugation and stored at −80°C until mass spec-
trometric analysis.
LC-MS/MS analysis
In the integrated quantitative proteomics and phosphoproteomics
workﬂow, the pooled TMT-labelled samples were fractionated using
an Ultimate 3000 nanoHPLC system in line with an Orbitrap Fusion
Tribrid mass spectrometer (Thermo Fisher Scientiﬁc). In brief,
peptides in 1% (vol/vol) formic acid (FA) were injected onto an
Acclaim PepMap C18 nano-trap column (Thermo Fisher Scientiﬁc).
After washing with 0.5% (vol/vol) acetonitrile, 0.1% (vol/vol) FA,
peptides were resolved on a 250 mm × 75 μm Acclaim PepMap C18
reverse-phase analytical column (Thermo Fisher Scientiﬁc) over a
150-min organic gradient, using six gradient segments (5–9% sol-
vent B over 2 min, 9–25% B over 94 min, 25–60% B over 23 min,
60–90% B over 5 min, held at 90% B for 5 min, and then reduced to
1% B over 2 min) with a ﬂow rate of 300 nl/min. Solvent A was 0.1%
FA and solvent B was aqueous 80% acetonitrile in 0.1% FA. Peptides
were ionized by nano-electrospray ionization at 2.0 kV using a
stainless-steel emitter with an internal diameter of 30 μm (Thermo
Fisher Scientiﬁc) and a capillary temperature of 275°C. All spectra
were acquired using an Orbitrap Fusion Tribrid mass spectrometer
controlled by Xcalibur software version 2 (Thermo Fisher Scientiﬁc)
and operated in data-dependent acquisition mode using a syn-
chronous precursor selection-MS3 workﬂow. FTMS1 spectra were
collected at a resolution of 120,000, with an AGC target of 200,000 and a
max injection time of 50 ms. Precursors were ﬁltered with an intensity
threshold of 5,000, according to charge state (to include charge
states 2–7) and with monoisotopic precursor selection. Previously
interrogated precursors were excluded using a dynamic window (60
s ± 10 ppm). The MS2 precursors were isolated with a quadrupole
mass ﬁlter set to a width of 1.2 m/z. ITMS2 spectra were collected
with an AGC target of 10,000, max injection time of 70 ms and
collision-induced dissociation energy of 35%. For FTMS3 analysis,
the Orbitrap was operated at 50,000 resolution with an AGC target of
50,000 and a maximum injection time of 105 ms. Precursors were
fragmented by high-energy collision dissociation (HCD) at a nor-
malized collision energy of 60% to ensuremaximal TMT reporter ion
yield. SPS was enabled to include up to ﬁve MS2 fragment ions in
the FTMS3 scan.
In TPP and kinase enrichment experiments, peptide mixtures
from TMT 10-plex labelled samples were chromatographically re-
solved on an EASY-spray PepMap RSLC C18 column (2 μm, 100 A˚, 75
μm × 50 cm ID) using an Ultimate 3000 RSLCnano system (Thermo
Fisher Scientiﬁc) over a 180-min gradient at 40°C. Six gradient
segments (2–8% solvent B over 3 min 30 s, 8–25% B over 98 min 30 s,
25–40% B over 45 min, 40–95% B over 5 min, held at 95% B for 5 min,
and then reduced to 2% B over 1 min and for the rest of the ac-
quisition) were applied with a ﬂow rate of 250 nl/min. Two gradient
segments (2–35% solvent B over 153 min, then increased to 95% in
1 min and held at 95% B for 11 min and then reduced to 2% B over
1 min and for the rest of the acquisition) were applied in TPP ex-
periments. Solvent A was 0.1% FA and 5% DMSO in HPLC-grade
water, and solvent B was 0.1% FA and 5% DMSO in 80% acetonitrile.
All spectra were acquired using an Orbitrap Fusion Lumos Tribrid
mass spectrometer (Thermo Fisher Scientiﬁc). Xcalibur (version 2
and 4) software (Thermo Fisher Scientiﬁc) was used to control data
acquisition. The instrument was operated in data-dependent ac-
quisition mode, and the most abundant peptides selected for MS/
MS were fragmented by HCD fragmentation techniques. MS spectra
were acquired at a resolution of 120,000, and an ion target of 4E5.
HCD scans were performed with 38% normalized collision energy at
50,000 resolution (at 100 m/z), and the ion target settings were set
to 1E5. Precursors were ﬁltered with an intensity threshold of 5,000,
according to charge state (to include charge states 2–6) and with
monoisotopic precursor selection.
In vitro kinase assays
The Reaction Biology (http://www.reactionbiology.com) “HotSpot”
assay platform was used to validate inhibition of different kinases
by circadian period–altering compounds as identiﬁed in the pro-
teomic approach using desthiobiotin nucleotide probes. In vitro
proﬁling of selected kinase panels was performed following the
same protocol as described by Anastassiadis et al (2011). In brief,
speciﬁc kinase/substrate pairs were mixed in a buffer containing
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20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/
ml BSA, 0.1 mM Na3VO4, 2 mM DTT, and 1% DMSO. Circadian
rhythm–modulating compounds (longdaysin, purvalanol A, rosco-
vitine, and SP600125) were then added to each reaction mixture.
After a 20-min incubation, ATP (cat. no. A7699; Sigma-Aldrich) and
[γ-33P] ATP (cat. no. NEG602H001MC; PerkinElmer) were added at a
ﬁnal total concentration of 10 mM. Reaction mixers were incubated
at 25°C for 120 min and spotted onto P81 ion exchange cellulose
chromatography paper (cat. no. 05-717; Whatman). Unbound
phosphate was removed by washing the ﬁlters in 0.75% phosphoric
acid for multiple times. After subtraction of background derived
from control reactions containing inactive enzyme, kinase activity
data were expressed as the percent remaining kinase activity in
treated samples compared with vehicle (DMSO) reactions. 10-dose
inhibition curves (threefold serial dilution starting at 100 μM) were
used to derive the IC50 values and curve ﬁts were obtained using
Prism (GraphPad Prism, version 8.1.0).
Database search for peptide and protein identiﬁcation
Quantitative proteomics and phosphoproteomics, and TPP raw data
ﬁles were analysed using the MaxQuant computational platform
(version 1.5.2.8) with the Andromeda search engine (Cox&Mann, 2008).
MS2/MS3 spectra were searched against UniProt database specifying
Homo sapiens (Human) taxonomy (proteome ID: UP000005640; or-
ganism ID: 9606; protein count: 73,920). All searches were performed
using “Reporter ion MS2/MS3” with “10-plex TMT” as isobaric labels
with a static modiﬁcation for cysteine alkylation (carbamidome-
thylation) and oxidation of methionine (M) and protein N-terminal
acetylation as the variable modiﬁcations. Phospho (STY) was in-
cluded as an additional variable modiﬁcation for the phospho-
peptide enriched samples. Trypsin digestion with maximum one
missed cleavage, minimum peptide length as seven amino acids,
precursor ion mass tolerance of 5 ppm, and fragment mass tol-
erance of 0.02 kD was speciﬁed in all analyses. The FDR was kept at
0.01 for peptide spectrum match, protein, and site decoy fraction.
TMT signals were corrected for isotope impurities based on the
manufacturer’s instructions.
The raw data ﬁles for kinase enrichment analysis were processed
and quantiﬁed using Proteome Discoverer software version 1.4
(Thermo Fisher Scientiﬁc) and were searched against the UniProt
Human database using the SEQUEST algorithm. Peptide precursor
mass tolerance was set at 10 ppm, and MS/MS tolerance was set at
0.06 kD. Search criteria included oxidation of methionine (M), TMT
to lysine, and desthiobiotin lysine (K) as variable modiﬁcations,
whereas carbamidomethylation of cysteine and TMT to peptide N
termini were included as ﬁxed modiﬁcations. Searches were per-
formed with full tryptic digestion and a maximum of one missed
cleavage was allowed. All peptide data were ﬁltered at high (1%)
and medium (5%) FDR.
Statistical analysis of quantitative proteomics and kinase assay
data
Unless otherwise mentioned, all experiments were conducted with
biological replicates and at least two independent experiments
were performed. Processing and statistical analysis of quantitative
proteomics and phosphoproteomics datasets were performed
using the Perseus workstation (version 1.5.5.3) (Tyanova et al, 2016).
During data processing, reverse and contaminant database hits and
candidates identiﬁed only by site were ﬁltered out. In differential
quantitative proteomics analyses (control versus compound-treated
groups), categorical annotation was applied to group reporter ion
intensities, values were log2 transformed, and were normalized by
“subtract mean (column-wise)” in each TMT reporter ion channel.
Protein groups were ﬁltered for valid values (at least 80% in each
group), and P-values obtained from a paired t test were used to
determine the signiﬁcance of differences in protein or phosphosite
abundances between control and compound-treated groups. P-value
(adjusted) < 0.05 were considered as statistically signiﬁcant.
GraphPad Prism 8 and XLSTAT were used for performing sta-
tistical tests for kinase assay data. Succeeding one-way ANOVA,
Dunnett’s test was performed to compare every (compound-
treated groups) mean to a control (DMSO) mean. P-value < 0.05
was considered statistically signiﬁcant. Venny version 2.1 was ap-
plied to generate the Venn diagrams for detecting overlaps among
different conditions.
TPP data analysis
In TPP quantitative proteomics experiments, fold-changes were
calculated by using the lowest temperature condition (37°C) as the
reference. These fold-change values indicate the relative amount of
nondenatured protein at the corresponding temperature. Curve
ﬁtting (relative fold-changes as a function of temperature), nor-
malization, and assessment of slope and melting point differences
were performed using the TR workﬂow of the TPP R package
(Franken et al, 2015). Subsequent to a global normalization pro-
cedure (Savitski et al, 2014), melting curves were ﬁtted for all
proteins identiﬁed in the vehicle- and compound-treated experi-
ments. Melting point differences and slope differences were cal-
culated for proteins for which the melting curves passed the
following two requirements: (i) both ﬁtted curves for the vehicle-
and compound-treated condition had an R2 of greater than 0.8, and
(ii) the vehicle curve had a plateau of less than 0.3. Subsequently,
four ﬁlters were used to determine the quality of the result for each
protein. (i) Minimum slope in each of the control versus treatment
experiments <−0.06. (ii) Both the melting point differences in the
control versus treatment experiments greater than the melting point
difference between the twountreated controls. (iii) One of the P values
(FDR corrected) for the two replicate experiments <0.1. (iv) Melting
point shifts in both the control versus treatment experiments have a
positive sign (i.e., protein was stabilized in both cases). Candidates
satisfying all these selection criteria were considered as the potential
cellular targets for circadian period–altering compounds.
Interaction network and bioinformatics analysis
Functional annotation and clustering of the differentially abundant
proteins and phosphosites and altered kinases identiﬁed in circadian
rhythm–modulating compound–treated cells were performed us-
ing Protein ANalysis THrough Evolutionary Relationships (PANTHER)
classiﬁcation system, version 12.0 (Mi et al, 2013), IPA (QIAGEN), and
Reactome pathway Knowledgebase, version 62 (Fabregat et al,
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2016). Statistical overrepresentation test was performed to select
the Gene Ontology terms overexpressed (FDR < 0.05) for the differ-
entially abundant candidates. In addition, Proteomaps were used to
assign proteins to functional categories (KEGG Pathways gene clas-
siﬁcation) (Liebermeister et al, 2014). Protein association networks
were generated using the STRING database, version 11.0 (Szklarczyk
et al, 2019) involving only high-conﬁdence (score > 0.8) interactions.
siRNA knockdown data for the differentially abundant proteins, al-
tered kinases, and potential cellular targets for circadian period–
altering compounds were obtained from BioGPS circadian layout
database (Zhang et al, 2009). Kinome tree visualization and annotation
were performed using KinMap web-based tool (Eid et al, 2017).
Data availability
The MS proteomics, phosphoproteomics, kinome proﬁle, and
TPP data described in this article are deposited to the Proteo-
meXchange Consortium via the PRIDE (Perez-Riverol et al, 2019)
partner repository with the dataset identiﬁer PXD014186.
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